On Tuesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) was -2.65% drop from the session before settling in for the closing price of $1.13. A 52-week range for ACRS has been $0.95 – $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 72.53% over the past five years. When this article was written, the company’s average yearly earnings per share was at 60.09%. With a float of $91.67 million, this company’s outstanding shares have now reached $107.85 million.
Let’s look at the performance matrix of the company that is accounted for 64 employees. In terms of profitability, gross margin is 17.43%, operating margin of -728.22%, and the pretax margin is -705.44%.
Aclaris Therapeutics Inc (ACRS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aclaris Therapeutics Inc stocks. The insider ownership of Aclaris Therapeutics Inc is 15.34%, while institutional ownership is 68.62%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.73% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
You can see what Aclaris Therapeutics Inc (ACRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ: ACRS) saw its 5-day average volume 0.93 million, a positive change from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 24.57%. Additionally, its Average True Range was 0.11.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 1.57%, which indicates a significant decrease from 9.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.84% in the past 14 days, which was higher than the 63.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6870, while its 200-day Moving Average is $1.9049. Nevertheless, the first resistance level for the watch stands at $1.1533 in the near term. At $1.2067, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2333. If the price goes on to break the first support level at $1.0733, it is likely to go to the next support level at $1.0467. The third support level lies at $0.9933 if the price breaches the second support level.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
There are 108,281K outstanding shares of the company, which has a market capitalization of 119.11 million. As of now, sales total 18,720 K while income totals -132,070 K. Its latest quarter income was 9,210 K while its last quarter net income were -96,550 K.
